1 Stock That Should Be in Every Investor's Portfolio

It's not often that something as influential as an effective weight loss drug comes on the market. Eli Lilly (NYSE: LLY) has that product. They also have a leading treatment for diabetes and a burgeoning treatment for Alzheimer's. These multiple treatment avenues have the company set to rake in quite a bit of money as long as they don't screw it up.My general take here is that the remarkable revenue growth we saw last year can continue moving forward. Obesity is a major factor, especially in the United States, and a drug like Zepbound stands to receive serious demand as more and more people learn about its potential. Even with its volatility and modestly higher valuation, I think Eli Lilly has room to run.Eli Lilly is the largest healthcare company with a total market valuation of over $700 billion. Mounjaro is its leading drug. Used to treat type 2 diabetes, it brought in roughly $5.2 billion worldwide in Q2 revenue. That marks a 68% increase year over year. In the U.S. alone, revenue increased 37% to $3.3 billion.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool